In the era of precision medicine, patient eligibility for clinical trials is frequently based on histological and molecular tumor profiling. Central pathological review of primary diagnosis is often prerequisite for trial entry, especially in trials for rare tumor patients. In addition, central review for tumor regression grade assessment is required, whenever this is used as a surrogate endpoint to expedite the trial.
Smaller scale, pivotal, biomarker driven studies are gaining acceptance among cancer clinical researchers and are gaining preference over large phase 3 trials. Here, with these targeted trials, it is often the pathologist who confirms biomarker positivity for patient registration. Validation of companion diagnostics is integrated in a number of EORTC trials and is often assisted by pathologists at the central laboratories.
Quality assessed clinically annotated biobanks with longitudinally collected information for optimized patient access are essential to therapeutic biomarker-driven clinical trials and new biomarker discovery. Pathologists are responsible for assessment of sample quality at entry and for maintaining the long term integrity of the EORTC associated biobanks. Quality assurance of biobanks and some of the preanalytical and analytical methods are safeguarded by EORTC Pathobiology group with the assistance of the translational research team at EORTC HQ.
Given the crucial role of pathologists at EORTC trials, ESP and EORTC have developed a scientific initiative focusing on cancer clinical research and fellowship programs.
In light of the fact that pathology and pathologists play an increasingly important role in clinical trials, especially in the field of medical oncology, the EORTC and ESP invite young pathologists to apply for a joint ESP-EORTC Fellowship.
Interested? Please visit: www.eortc.org/careers
In light of the fact that pathology and pathologists play an increasingly important role in clinical trials, especially in the field of medical oncology, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Pathology (ESP) invite young pathologists to apply for a joint ESP-EORTC Fellowship based at the EORTC research facility based in Brussels.
The main objective of the ESP – EORTC Fellowship is to study and report about pathology practice in the framework of EORTC trials and to provide support for studies with a pathology component.
The fellowship is for a duration of one year and renewable up to a maximum of three years at EORTC Headquarters in Brussels, Belgium.
Candidates must:
Candidates must send:
to:
Saïda Jinah
EORTC Fellowship Program
Avenue E. Mounier 83 b/11, 1200 Brussels, Belgium
Phone: +32 27741650
E-mail: saida.jinah@eortc.be
“My name is Maria Urbanowicz and I am the new ESP-EORTC pathology fellow. A medical specialist in Pathology, I graduated from the University of Medical Sciences in Poznan, Poland and did my specialty at the 12 de Octubre University Hospital in Madrid, Spain.
This is the just the beginning of my Brussels adventure, at the EORTC and I look forward to contributing with my expertise to clinical research programs. I chose this fellowship program because I am open to new experience and I like challenges. As my routine work as an assistant consisted of reviewing biopsies, I believe that for a pathologist, being involved in clinical research is a totally new experience.
This is a big change for me and I will be doing my best to put my knowledge and experience into practice to the EORTC projects. This fellowship is a fantastic learning opportunity for which I am extremely grateful. I think it is important for a pathologist to get a broader vision concerning research activities and to grasp the role played by diagnosis in clinical trials and the importance of a detailed assessment and accurate diagnosis of samples for a successful clinical study.
I hope to make the most of my stay in Brussels! ”